Number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
and	O
their	O
sensitivity	O
to	O
hormone	O
action	O
.	O

The	O
study	O
demonstrated	O
a	O
decreased	O
level	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
hypercholesterolemic	O
subjects	O
,	O
and	O
an	O
elevated	O
level	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
.	O

In	O
the	O
lymphocytes	B-cell_type
with	O
a	O
high	O
GR	B-protein
number	O
,	O
dexamethasone	O
inhibited	O
[	O
3H	O
]	O
-thymidine	O
and	O
[	O
3H	O
]	O
-acetate	O
incorporation	O
into	O
DNA	O
and	O
cholesterol	O
,	O
respectively	O
,	O
in	O
the	O
same	O
manner	O
as	O
in	O
the	O
control	B-cell_type
cells	I-cell_type
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
decreased	O
GR	B-protein
number	O
resulted	O
in	O
a	O
less	O
efficient	O
dexamethasone	O
inhibition	O
of	O
the	O
incorporation	O
of	O
labeled	O
compounds	O
.	O

These	O
data	O
showed	O
that	O
the	O
sensitivity	O
of	O
lymphocytes	B-cell_type
to	O
glucocorticoids	O
changed	O
only	O
with	O
a	O
decrease	O
of	O
GR	B-protein
level	O
.	O

[	O
1	B-protein
,	I-protein
25-Dihydroxyvitamin	I-protein
D3	I-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
and	O
T-	B-cell_type
and	I-cell_type
B-lymphocyte	I-cell_type
count	O
in	O
patients	O
with	O
glomerulonephritis	O
]	O

Content	O
of	O
receptors	O
to	O
hormonal	O
form	O
of	O
vitamin	O
D3	O
,	O
1.25	O
(	O
OH	O
)	O
2D3	O
,	O
constituted	O
27.3	O
fmole/mg	O
of	O
protein	O
in	O
lymphocytes	B-cell_type
of	O
peripheric	O
blood	O
of	O
children	O
with	O
glomerulonephritis	O
.	O

In	O
the	O
patients	O
concentration	O
of	O
total	O
and	O
ionized	O
form	O
of	O
Ca2+	O
was	O
decreased	O
down	O
to	O
2.04	O
mmole/L	O
and	O
1.09	O
mmole/L	O
,	O
respectively	O
,	O
while	O
an	O
increase	O
in	O
parathormone	O
(	O
PTH	O
)	O
by	O
36	O
%	O
and	O
a	O
distinct	O
decrease	O
in	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
(	O
lower	O
than	O
1.25	O
ng/ml	O
)	O
was	O
found	O
in	O
blood	O
;	O
content	O
of	O
cAMP	O
was	O
also	O
decreased	O
in	O
lymphocytes	O
by	O
33	O
%	O
.	O

At	O
the	O
same	O
time	O
,	O
total	O
content	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
was	O
decreased	O
1.5-fold	O
in	O
peripheric	O
blood	O
.	O

Treatment	O
with	O
I-hydroxyvitamin	O
D3	O
(	O
1-1.5	O
mg	O
daily	O
,	O
within	O
4	O
weeks	O
)	O
led	O
to	O
normalization	O
of	O
total	O
and	O
ionized	O
form	O
of	O
Ca2+	O
and	O
of	O
25	O
(	O
OH	O
)	O
D	O
,	O
but	O
did	O
not	O
affect	O
the	O
PTH	O
content	O
in	O
blood	O
.	O

Concentration	O
of	O
the	O
receptors	B-protein
to	O
1.25	O
(	O
OH	O
)	O
2D3	O
was	O
elevated	O
up	O
to	O
39.7	O
fmole/mg	O
after	O
I	O
week	O
of	O
the	O
treatment	O
,	O
whereas	O
it	O
was	O
decreased	O
to	O
the	O
initial	O
level	O
24.8	O
fmole/mg	O
within	O
4	O
weeks	O
;	O
simultaneous	O
alteration	O
in	O
the	O
cAMP	O
content	O
was	O
observed	O
in	O
lymphocytes	B-cell_type
.	O

Treatment	O
with	O
1-	O
(	O
OH	O
)	O
D3	O
normalized	O
also	O
the	O
T	B-cell_type
lymphocytes	I-cell_type
content	O
in	O
peripheric	O
blood	O
.	O

The	O
data	O
obtained	O
suggest	O
that	O
under	O
conditions	O
of	O
glomerulonephritis	O
only	O
high	O
content	O
of	O
receptors	B-protein
to	O
1.25	O
(	O
OH	O
)	O
2D3	O
in	O
lymphocytes	B-cell_type
enabled	O
to	O
perform	O
the	O
cell	O
response	O
to	O
the	O
hormone	O
effect	O
.	O

Tumor	O
and	O
serum	O
beta-2-microglobulin	O
expression	O
in	O
women	O
with	O
breast	O
cancer	O
.	O

To	O
investigate	O
whether	O
the	O
tumor	B-cell_type
expression	O
of	O
beta-2-microglobulin	B-protein
(	O
beta	B-protein
2-M	I-protein
)	O
could	O
serve	O
as	O
a	O
marker	O
of	O
tumor	O
biologic	O
behavior	O
,	O
the	O
authors	O
studied	O
specimens	O
of	O
breast	B-cell_type
carcinomas	I-cell_type
from	O
60	O
consecutive	O
female	O
patients	O
.	O

Presence	O
of	O
beta	B-protein
2-M	I-protein
was	O
analyzed	O
by	O
immunohistochemistry	O
.	O

No	O
significant	O
correlations	O
were	O
found	O
between	O
tumor	B-protein
beta	I-protein
2-M	I-protein
expression	O
and	O
several	O
histologic	O
attributes	O
such	O
as	O
type	O
,	O
histologic	O
and	O
nuclear	O
grades	O
,	O
mitotic	O
index	O
,	O
necrosis	O
,	O
vascular	O
invasion	O
,	O
and	O
lymphocytic	O
infiltration	O
.	O

Likewise	O
,	O
beta	B-protein
2-M	I-protein
was	O
not	O
associated	O
with	O
markers	O
of	O
disease	O
extension	O
such	O
as	O
TNM	O
,	O
(	O
UICC	O
,	O
classification	O
of	O
malignant	B-cell_type
tumors	I-cell_type
)	O
staging	O
and	O
axillary	O
lymph	O
node	O
involvement	O
or	O
with	O
estrogen	O
,	O
progesterone	O
,	O
and	O
glucocorticoid	O
receptor	O
levels	O
.	O

However	O
,	O
there	O
was	O
a	O
significantly	O
positive	O
association	O
between	O
tumor	B-protein
beta	I-protein
2-M	I-protein
expression	O
and	O
the	O
degree	O
of	O
lymphocytic	O
infiltration	O
in	O
the	O
tumor	O
tissue	O
.	O

Beta	B-protein
2-M	I-protein
serum	O
levels	O
were	O
determined	O
by	O
an	O
enzyme-linked	O
immunosorbent	O
assay	O
in	O
samples	O
from	O
22	O
of	O
the	O
above	O
women	O
.	O

Although	O
some	O
of	O
the	O
highest	O
values	O
had	O
been	O
obtained	O
in	O
women	O
with	O
larger	O
(	O
T4	O
)	O
primary	O
tumors	O
,	O
the	O
authors	O
failed	O
to	O
detect	O
any	O
statistical	O
relationship	O
between	O
beta	B-protein
2-M	I-protein
expression	O
in	O
the	O
tumor	O
with	O
serum	O
levels	O
or	O
between	O
serum	B-protein
beta	I-protein
2-M	I-protein
and	O
the	O
above	O
histologic	O
,	O
laboratory	O
,	O
and	O
clinical	O
factors	O
.	O

[	O
Preliminary	O
observation	O
of	O
level	O
free-form	B-protein
E	I-protein
receptor	I-protein
levels	O
in	O
serum	O
of	O
normal	O
childbearing-aged	O
and	O
pregnant	O
women	O
]	O

In	O
137	O
cases	O
of	O
childbearing-aged	O
and	O
pregnant	O
women	O
,	O
free	B-protein
form	I-protein
E	I-protein
receptor	I-protein
levels	O
(	O
sE	B-protein
)	O
in	O
serum	O
were	O
measured	O
by	O
ELISA	O
.	O

The	O
level	O
of	O
sE	B-protein
was	O
significantly	O
decreased	O
during	O
the	O
first	O
trimester	O
,	O
slightly	O
higher	O
in	O
the	O
second	O
trimester	O
,	O
and	O
recovered	O
to	O
normal	O
in	O
the	O
third	O
trimester	O
.	O

The	O
level	O
remained	O
lower	O
in	O
29	O
PIH	O
women	O
but	O
appeared	O
higher	O
in	O
overdue	O
pregnancies	O
as	O
compared	O
with	O
the	O
normal	O
3rd	O
trimester	O
range	O
.	O

The	O
results	O
indicate	O
that	O
there	O
is	O
a	O
relationship	O
between	O
a	O
change	O
in	O
T	B-cell_type
cell	I-cell_type
function	O
and	O
pregnancy	O
.	O

Kappa	B-protein
B-specific	I-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
:	O
role	O
in	O
the	O
regulation	O
of	O
human	B-DNA
interleukin-2	I-DNA
gene	I-DNA
expression	O
.	O

Transcriptional	O
activation	O
of	O
the	O
human	B-DNA
interleukin-2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
,	O
like	O
induction	O
of	O
the	O
IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
and	O
the	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
,	O
is	O
shown	O
to	O
be	O
modulated	O
by	O
a	O
kappa	B-protein
B-like	I-protein
enhancer	I-protein
element	I-protein
.	O

Mutation	O
of	O
a	O
kappa	B-DNA
B	I-DNA
core	I-DNA
sequence	I-DNA
identified	O
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
(	O
-206	O
to	O
-195	O
)	O
partially	O
inhibits	O
both	O
mitogen-	O
and	O
HTLV-I	O
Tax-mediated	O
activation	O
of	O
this	O
transcription	B-protein
unit	I-protein
and	O
blocks	O
the	O
specific	O
binding	O
of	O
two	O
inducible	B-protein
cellular	I-protein
factors	I-protein
.	O

These	O
kappa	B-protein
B-specific	I-protein
proteins	I-protein
(	O
80	O
to	O
90	O
and	O
50	O
to	O
55	O
kilodaltons	O
)	O
similarly	O
interact	O
with	O
the	O
functional	O
kappa	B-protein
B	I-protein
enhancer	I-protein
present	O
in	O
the	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
.	O

These	O
data	O
suggest	O
that	O
these	O
kappa	B-protein
B-specific	I-protein
proteins	I-protein
have	O
a	O
role	O
in	O
the	O
coordinate	O
regulation	O
of	O
this	O
growth	O
factor-growth	O
factor	O
receptor	O
gene	O
system	O
that	O
controls	O
T	B-cell_type
cell	I-cell_type
proliferation	O
.	O

Novel	O
region	O
within	O
the	O
V	B-DNA
kappa	I-DNA
gene	I-DNA
promoter	I-DNA
is	O
responsible	O
for	O
tissue	O
and	O
stage-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
in	O
human	B-cell_type
lymphoid	I-cell_type
neoplasms	I-cell_type
.	O

Immunoglobulin	B-protein
gene-specific	I-protein
transacting	I-protein
factors	I-protein
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
lymphoid	O
tissue-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

The	O
role	O
of	O
these	O
factors	O
in	O
B-cell	B-cell_type
differentiation	O
and	O
stage-specific	O
expression	O
of	O
these	O
genes	O
is	O
,	O
however	O
,	O
not	O
fully	O
understood	O
.	O

We	O
have	O
used	O
a	O
model	O
of	O
human	O
lymphoid	O
neoplasia	O
to	O
address	O
this	O
question	O
.	O

Different	O
fragments	O
of	O
unrearranged	B-DNA
human	I-DNA
variable	I-DNA
region	I-DNA
of	O
immunoglobulin	B-DNA
kappa	I-DNA
gene	I-DNA
(	O
V	B-DNA
kappa	I-DNA
)	O
were	O
used	O
for	O
cell-free	O
in	O
vitro	O
transcription	O
and	O
DNA	O
mobility	O
shift	O
assays	O
.	O

Previously	O
described	O
enhancement	O
of	O
in	O
vitro	O
transcription	O
that	O
was	O
only	O
seen	O
with	O
nuclear	O
extracts	O
derived	O
from	O
B-cell	B-cell_type
neoplasms	I-cell_type
corresponding	O
to	O
the	O
late	O
stages	O
of	O
B-cell	B-cell_type
differentiation	O
was	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
actions	O
of	O
these	O
factor	O
(	O
s	O
)	O
on	O
the	O
DNA	O
region	O
within	O
the	O
V	B-DNA
kappa	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

This	O
region	O
is	O
located	O
within	O
the	O
920	O
bp	O
fragment	O
located	O
210	O
bp	O
upstream	O
from	O
the	O
coding	O
region	O
and	O
this	O
fragment	O
represents	O
a	O
possible	O
novel	O
DNA	O
region	O
,	O
which	O
plays	O
a	O
role	O
in	O
the	O
stage-	O
and	O
tissue-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

[	O
Determination	O
of	O
the	O
sensitivity	O
to	O
glucocorticoids	B-protein
in	O
vitro	O
]	O

A	O
modified	O
method	O
for	O
the	O
determination	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
is	O
suggested	O
.	O

The	O
principal	O
distinction	O
of	O
the	O
method	O
is	O
standardization	O
by	O
the	O
lymphocyte	B-cell_type
count	O
in	O
a	O
sample	O
(	O
1	O
mln	O
)	O
and	O
the	O
labeled	O
hormone	B-protein
concentration	O
.	O

The	O
modification	O
saves	O
time	O
and	O
money	O
,	O
limits	O
the	O
range	O
of	O
the	O
data	O
variations	O
,	O
and	O
makes	O
use	O
of	O
a	O
lesser	O
volume	O
of	O
blood	O
.	O

Examinations	O
of	O
70	O
children	O
aged	O
4	O
to	O
15	O
suffering	O
from	O
the	O
nephrotic	O
form	O
of	O
glomerulonephritis	O
have	O
made	O
it	O
possible	O
to	O
distinguish	O
two	O
groups	O
of	O
patients	O
:	O
with	O
relatively	O
high	O
values	O
of	O
specific	O
binding	O
X	O
=	O
6820.1	O
+/-	O
530.0	O
(	O
n	O
=	O
30	O
,	O
p	O
=	O
0.95	O
,	O
t	O
=	O
2.04	O
)	O
,	O
this	O
corresponding	O
to	O
a	O
clinical	O
form	O
of	O
hormone	B-protein
-sensitive	O
glomerulonephritis	O
,	O
and	O
with	O
relatively	O
low	O
values	O
of	O
specific	O
binding	O
X	O
=	O
1815.2	O
+/-	O
302.8	O
(	O
n	O
=	O
40	O
,	O
p	O
=	O
0.95	O
,	O
t	O
=	O
1.96	O
)	O
,	O
that	O
corresponds	O
to	O
hormone	B-protein
-resistant	O
glomerulonephritis	O
.	O

Dynamic	O
studies	O
have	O
not	O
shown	O
any	O
statistically	O
significant	O
changes	O
in	O
the	O
specific	O
binding	O
values	O
.	O

These	O
results	O
permit	O
regarding	O
the	O
specific	O
binding	O
value	O
as	O
a	O
prognostic	O
criterion	O
in	O
the	O
assessment	O
of	O
corticosteroid	B-protein
therapy	O
;	O
this	O
allows	O
a	O
wide	O
employment	O
of	O
the	O
described	O
method	O
in	O
practical	O
nephrology	O
.	O

Octamer-binding	B-protein
proteins	I-protein
from	O
B	B-cell_line
or	I-cell_line
HeLa	I-cell_line
cells	I-cell_line
stimulate	O
transcription	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
promoter	I-DNA
in	O
vitro	O
.	O

The	O
B-cell	B-cell_type
-type	O
specificity	O
of	O
the	O
immunoglobulin	B-protein
(	O
Ig	B-protein
)	O
heavy-chain	O
and	O
light-chain	O
promoters	O
is	O
mediated	O
by	O
an	O
octanucleotide	B-DNA
(	I-DNA
OCTA	I-DNA
)	I-DNA
element	I-DNA
,	O
ATGCAAAT	O
,	O
that	O
is	O
also	O
a	O
functional	O
component	O
of	O
other	O
RNA	B-DNA
polymerase	I-DNA
II	I-DNA
promoters	I-DNA
,	O
such	O
as	O
snRNA	O
and	O
histone	O
H2B	O
promoters	O
.	O

Two	O
nuclear	B-protein
proteins	I-protein
that	O
bind	O
specifically	O
and	O
with	O
high	O
affinity	O
to	O
the	O
OCTA	B-DNA
element	I-DNA
have	O
been	O
identified	O
.	O

NF-A1	B-protein
is	O
present	O
in	O
a	O
variety	O
of	O
cell	O
types	O
,	O
whereas	O
the	O
presence	O
of	O
NF-A2	B-protein
is	O
essentially	O
confined	O
to	O
B	B-cell_type
cells	I-cell_type
,	O
leading	O
to	O
the	O
hypothesis	O
that	O
NF-A2	B-protein
activates	O
cell-type-specific	O
transcription	O
of	O
the	O
Ig	B-DNA
promoter	I-DNA
and	O
NF-A1	B-protein
mediates	O
the	O
other	O
responses	O
of	O
the	O
OCTA	B-DNA
element	I-DNA
.	O

Extracts	O
of	O
the	O
B-cell	B-cell_line
line	I-cell_line
,	O
BJA-B	B-cell_line
,	O
contain	O
high	O
levels	O
of	O
NF-A2	B-protein
and	O
specifically	O
transcribe	O
Ig	B-DNA
promoters	I-DNA
.	O

In	O
contrast	O
,	O
extracts	O
from	O
HeLa	B-cell_line
cells	I-cell_line
transcribed	O
the	O
Ig	B-DNA
promoter	I-DNA
poorly	O
.	O

Surprisingly	O
,	O
addition	O
of	O
either	O
affinity-enriched	O
NF-A2	O
or	O
NF-A1	O
to	O
either	O
a	O
HeLa	O
extract	O
or	O
a	O
partially	O
purified	O
reaction	O
system	O
specifically	O
stimulates	O
the	O
Ig	B-DNA
promoter	I-DNA
.	O

This	O
suggests	O
that	O
the	O
constitutive	O
OCTA-binding	B-protein
factor	I-protein
NF-A1	I-protein
can	O
activate	O
transcription	O
of	O
the	O
Ig	B-DNA
promoter	I-DNA
and	O
that	O
B-cell	B-cell_type
-specific	O
transcription	O
of	O
this	O
promoter	O
,	O
at	O
least	O
in	O
vitro	O
,	O
is	O
partially	O
due	O
to	O
a	O
quantitative	O
difference	O
in	O
the	O
amount	O
of	O
OCTA-binding	B-protein
protein	I-protein
.	O

Because	O
NF-A1	B-protein
can	O
stimulate	O
Ig	B-protein
transcription	O
,	O
the	O
inability	O
of	O
this	O
factor	O
to	O
activate	O
in	O
vivo	O
the	O
Ig	B-DNA
promoter	I-DNA
to	O
the	O
same	O
degree	O
as	O
the	O
snRNA	B-DNA
promoters	I-DNA
probably	O
reflects	O
a	O
difference	O
in	O
the	O
context	O
of	O
the	O
OCTA	B-DNA
element	I-DNA
in	O
these	O
two	O
types	O
of	O
promoters	B-DNA
.	O

Identification	O
of	O
a	O
putative	O
regulator	O
of	O
early	B-DNA
T	I-DNA
cell	I-DNA
activation	I-DNA
genes	I-DNA
.	O

Molecules	O
involved	O
in	O
the	O
antigen	O
receptor-dependent	O
regulation	O
of	O
early	B-DNA
T	I-DNA
cell	I-DNA
activation	I-DNA
genes	I-DNA
were	O
investigated	O
with	O
the	O
use	O
of	O
functional	O
sequences	O
of	O
the	O
T	B-protein
cell	I-protein
activation-specific	I-protein
enhancer	I-protein
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
.	O

One	O
of	O
these	O
sequences	O
forms	O
a	O
protein	O
complex	O
,	O
NFAT-1	B-protein
,	O
specifically	O
with	O
nuclear	O
extracts	O
of	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O

This	O
complex	O
appeared	O
10	O
to	O
25	O
minutes	O
before	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O

Studies	O
with	O
inhibitors	O
of	O
protein	O
synthesis	O
indicated	O
that	O
the	O
time	O
of	O
synthesis	O
of	O
the	O
activator	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
corresponds	O
to	O
the	O
time	O
of	O
appearance	O
of	O
NFAT-1	B-protein
.	O

NFAT-1	B-protein
,	O
or	O
a	O
very	O
similar	O
protein	O
,	O
bound	O
functional	O
sequences	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
;	O
the	O
LTR	B-DNA
of	O
this	O
virus	O
is	O
known	O
to	O
be	O
stimulated	O
during	O
early	O
T	B-cell_type
cell	I-cell_type
activation	O
.	O

The	O
binding	B-DNA
site	I-DNA
for	O
this	O
complex	O
activated	O
a	O
linked	O
promoter	O
after	O
transfection	O
into	O
antigen	B-cell_type
receptor-activated	I-cell_type
T	I-cell_type
cells	I-cell_type
but	O
not	O
other	O
cell	O
types	O
.	O

These	O
characteristics	O
suggest	O
that	O
NFAT-1	B-protein
transmits	O
signals	O
initiated	O
at	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
.	O

Characterization	O
of	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
in	O
human	B-cell_line
IM-9	I-cell_line
lymphocytes	I-cell_line
.	O

Although	O
putatively	O
identified	O
more	O
than	O
10	O
years	O
ago	O
,	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
in	O
human	O
tissues	O
remain	O
poorly	O
characterized	O
.	O

As	O
a	O
first	O
step	O
towards	O
understanding	O
the	O
mechanism	O
of	O
thyroid	O
hormone	O
action	O
in	O
man	O
we	O
have	O
characterized	O
T3	B-protein
binding	I-protein
sites	I-protein
in	O
nuclei	O
of	O
the	O
human	B-cell_line
lymphoblastoid	I-cell_line
line	I-cell_line
,	O
IM-9	B-cell_line
cells	I-cell_line
.	O

In	O
whole	O
cell	O
experiments	O
at	O
37	O
degrees	O
C	O
,	O
nuclear	O
binding	O
of	O
[	B-protein
125I	I-protein
]	I-protein
T3	I-protein
was	O
saturable	O
(	O
Kd	O
34	O
+/-	O
6	O
pmol/l	O
)	O
and	O
of	O
finite	O
capacity	O
(	O
approximately	O
equal	O
to	O
350	O
sites/cell	O
)	O
.	O

The	O
binding	B-protein
sites	I-protein
were	O
extracted	O
from	O
a	O
nuclear	O
pellet	O
by	O
treatment	O
with	O
0.4	O
mol/l	O
KCl	O
and	O
sonication	O
.	O

Separation	O
of	O
bound	O
from	O
free	O
[	B-protein
125I	I-protein
]	I-protein
T3	I-protein
in	O
the	O
extracts	O
was	O
achieved	O
using	O
the	O
calcium	O
phosphate	O
matrix	O
,	O
hydroxyapatite	O
at	O
a	O
concentration	O
of	O
0.3	O
ml	O
of	O
a	O
150	O
g/l	O
slurry	O
.	O

Rectilinear	O
Scatchard	O
plots	O
were	O
obtained	O
only	O
when	O
the	O
hydroxyapatite	O
was	O
washed	O
with	O
a	O
buffer	O
containing	O
0.5	O
%	O
Triton	O
X-100	O
.	O

Under	O
these	O
conditions	O
T3	B-protein
binding	I-protein
sites	I-protein
in	O
the	O
nuclear	O
extracts	O
were	O
present	O
at	O
a	O
concentration	O
of	O
22.4	O
+/-	O
8.6	O
fmol/mg	O
protein	O
and	O
showed	O
an	O
affinity	O
of	O
(	O
Kd	O
,	O
room	O
temperature	O
)	O
140	O
+/-	O
10	O
pmol/l	O
.	O

The	O
same	O
assay	O
system	O
was	O
used	O
to	O
determine	O
the	O
hierarchy	O
of	O
affinities	O
for	O
a	O
range	O
of	O
natural	O
and	O
synthetic	O
analogues	O
.	O

Calling	O
T3	O
100	O
,	O
the	O
order	O
of	O
potencies	O
observed	O
was	O
:	O
Triac	O
,	O
500	O
;	O
3	O
,	O
5-diiodo-3'-isopropylthyronine	O
,	O
89	O
;	O
T4	O
,	O
32	O
;	O
3	O
,	O
5-dimethyl-3'isopropylthyronine	O
2	O
;	O
3	O
,	O
5-T2	O
,	O
0.7	O
,	O
rT3	O
,	O
0.4	O
;	O
3'5'-T2	O
,	O
less	O
than	O
0.01	O
.	O

These	O
results	O
suggest	O
that	O
the	O
T3	B-protein
binding	I-protein
sites	I-protein
present	O
in	O
human	B-cell_line
IM-9	I-cell_line
lymphocyte	I-cell_line
nuclei	O
and	O
extracts	O
thereof	O
are	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
.	O

These	O
cells	O
may	O
be	O
a	O
useful	O
tool	O
to	O
increase	O
our	O
understanding	O
of	O
human	B-protein
T3	I-protein
receptors	I-protein

Definition	O
of	O
T-cell	B-protein
specific	I-protein
DNA-binding	I-protein
factors	I-protein
that	O
interact	O
with	O
a	O
3'-silencer	B-DNA
in	O
the	O
CD4+	B-DNA
T-cell	I-DNA
gene	I-DNA
Rpt-1	I-DNA
.	O

Analysis	O
of	O
the	O
region	O
3	O
'	O
to	O
the	O
CD4+	B-DNA
T-cell	I-DNA
gene	I-DNA
Rpt-1	I-DNA
(	O
encoding	O
regulatory	O
protein	O
T-lymphocyte	B-protein
1	I-protein
)	O
led	O
to	O
the	O
definition	O
of	O
a	O
silencer	B-DNA
element	I-DNA
that	O
inhibits	O
heterologous	B-DNA
gene	I-DNA
expression	O
in	O
certain	O
CD4+	B-cell_type
T-cell	I-cell_type
lines	I-cell_type
but	O
not	O
in	O
B-cell	B-cell_type
or	O
non-lymphoid	B-cell_type
cell	I-cell_type
lines	I-cell_type
.	O

Functional	O
silencer	B-DNA
activity	O
in	O
vivo	O
was	O
associated	O
with	O
the	O
presence	O
of	O
a	O
specific	O
silencer-DNA-protein	B-protein
complex	I-protein
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
with	O
T-cell	B-cell_type
extracts	O
.	O

Formation	O
of	O
this	O
complex	O
was	O
selectively	O
inhibited	O
by	O
the	O
region	O
in	O
HIV-1	B-DNA
containing	O
a	O
silencer	B-DNA
element	I-DNA
.	O

We	O
discuss	O
the	O
possibility	O
that	O
DNA-binding	B-protein
factors	I-protein
may	O
coregulate	O
HIV-1	O
and	O
Rpt-1	O
gene	O
expression	O
through	O
a	O
common	O
transcriptional	B-DNA
silencer	I-DNA
element	I-DNA
.	O

Congenital	O
immunodeficiencies	O
associated	O
with	O
absence	O
of	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
on	O
lymphocytes	B-cell_type
result	O
from	O
distinct	O
mutations	O
in	O
trans-acting	B-protein
factors	I-protein
.	O

Coordinate	O
regulation	O
of	O
HLA	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
expression	O
during	O
development	O
and	O
coinduction	O
of	O
class	B-DNA
II	I-DNA
genes	I-DNA
by	O
soluble	B-protein
factors	I-protein
suggests	O
that	O
common	O
trans-acting	B-protein
factor	I-protein
(	O
s	O
)	O
control	O
expression	O
of	O
these	O
genes	O
.	O

In	O
B-lymphoblastoid	B-cell_type
cell	I-cell_type
lines	I-cell_type
derived	O
from	O
two	O
independent	O
class	O
II-deficient	O
bare	O
lymphocyte	O
syndrome	O
patients	O
,	O
we	O
observed	O
a	O
drastic	O
decrease	O
in	O
transcription	O
rates	O
of	O
the	O
class	B-DNA
II	I-DNA
genes	I-DNA
.	O

When	O
these	O
cell	O
lines	O
are	O
fused	O
,	O
class	B-DNA
II	I-DNA
genes	I-DNA
are	O
reexpressed	O
,	O
indicating	O
that	O
immunodeficiencies	O
in	O
bare	O
lymphocyte	O
syndrome	O
patients	O
are	O
the	O
result	O
of	O
two	O
distinct	O
mutations	O
.	O

Further	O
studies	O
show	O
that	O
genes	O
governing	O
the	O
expression	O
of	O
class	B-protein
II	I-protein
antigens	I-protein
fall	O
into	O
at	O
least	O
three	O
complementation	O
groups	O
;	O
two	O
of	O
these	O
were	O
previously	O
unidentified	O
in	O
mutant	B-cell_line
cell	I-cell_line
lines	I-cell_line
generated	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
we	O
report	O
the	O
identification	O
of	O
two	O
discrete	O
complexes	O
,	O
NFX1.1	B-protein
and	O
NFX1.2	B-protein
,	O
that	O
bind	O
to	O
the	O
DRA	B-DNA
X	I-DNA
consensus	I-DNA
element	I-DNA
.	O

Though	O
the	O
mutation	O
in	O
at	O
least	O
one	O
mutant	B-cell_line
line	I-cell_line
generated	O
in	O
vitro	O
(	O
RJ2.2.5	B-cell_line
)	O
affects	O
products	O
functioning	O
via	O
interaction	O
with	O
the	O
X	B-DNA
box	I-DNA
,	O
clear	O
alterations	O
in	O
either	O
NFX1.1	B-protein
or	O
NFX1.2	B-protein
are	O
not	O
found	O
in	O
any	O
of	O
the	O
mutant	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

In	O
vivo	O
responsiveness	O
to	O
glucocorticoid	O
correlated	O
with	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
normal	O
humans	O
.	O

Dexamethasone	O
loading	O
tests	O
(	O
0.1	O
mg	O
dexamethasone/kg	O
,	O
iv	O
)	O
were	O
performed	O
in	O
18	O
normal	O
males	O
to	O
evaluate	O
the	O
individual	O
responsiveness	O
to	O
glucocorticoid	O
.	O

There	O
were	O
inter-individual	O
differences	O
in	O
increase	O
in	O
peripheral	B-cell_type
blood	I-cell_type
polymorphonuclear	I-cell_type
leukocyte	I-cell_type
count	O
,	O
decrease	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocyte	I-cell_type
count	O
,	O
and	O
increase	O
in	O
plasma	O
free	O
fatty	O
acids	O
levels	O
after	O
dexamethasone	O
injection	O
.	O

In	O
addition	O
,	O
there	O
was	O
a	O
significant	O
correlation	O
between	O
the	O
maximum	O
increase	O
in	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
and	O
the	O
maximum	O
decrease	O
in	O
lymphocytes	B-cell_type
(	O
r	O
=	O
0.7514	O
,	O
p	O
less	O
than	O
0.0003	O
)	O
.	O

Simultaneous	O
measurements	O
of	O
glucocorticoid	B-protein
receptor	I-protein
content	O
by	O
whole-cell	O
assay	O
revealed	O
that	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
linearly	O
correlated	O
with	O
that	O
in	O
the	O
corresponding	O
lymphocytes	B-cell_type
(	O
r	O
=	O
0.9482	O
,	O
p	O
less	O
than	O
0.0001	O
)	O
.	O

There	O
were	O
also	O
significant	O
correlations	O
between	O
the	O
maximum	O
increase	O
in	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
and	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
(	O
r	O
=	O
0.7239	O
,	O
p	O
less	O
than	O
0.0007	O
)	O
,	O
and	O
between	O
the	O
maximum	O
decrease	O
in	O
lymphocytes	B-cell_type
and	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
lymphocytes	B-cell_type
(	O
r	O
=	O
0.7703	O
,	O
p	O
less	O
than	O
0.0002	O
)	O
.	O

These	O
results	O
suggest	O
that	O
individual	O
differences	O
are	O
preserved	O
both	O
in	O
glucocorticoid	O
responsiveness	O
and	O
in	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
normal	O
humans	O
.	O

Estradiol	O
receptors	O
in	O
the	O
cytosol	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
in	O
hepatitis	O
B	O
virus	O
carriers	O
treated	O
with	O
interferon-alpha	B-protein
.	O

Estradiol	B-protein
receptors	I-protein
in	O
the	O
cytosol	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
the	O
effects	O
of	O
interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
on	O
estradiol	B-protein
receptors	I-protein
were	O
studied	O
in	O
asymptomatic	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
carriers	O
,	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
and	O
normal	O
controls	O
.	O

The	O
level	O
of	O
estradiol	B-protein
receptors	I-protein
in	O
the	O
cytosol	O
of	O
mononuclear	B-cell_type
cells	I-cell_type
was	O
significantly	O
lower	O
in	O
asymptomatic	O
HBV	O
carriers	O
and	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
,	O
compared	O
to	O
normal	O
controls	O
.	O

This	O
low	O
level	O
of	O
cytosol	O
estradiol	B-protein
receptors	I-protein
in	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
was	O
increased	O
by	O
the	O
administration	O
of	O
IFN-alpha	B-protein
.	O

In	O
addition	O
,	O
when	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
were	O
incubated	O
with	O
IFN-alpha	B-protein
in	O
vitro	O
,	O
the	O
level	O
of	O
cytosol	O
estradiol	B-protein
receptors	I-protein
also	O
increased	O
by	O
increasing	O
the	O
concentration	O
of	O
IFN-alpha	B-protein
.	O

We	O
previously	O
reported	O
that	O
the	O
response	O
of	O
mononuclear	B-cell_type
cells	I-cell_type
to	O
estrogen	O
is	O
impaired	O
in	O
HBV	O
carriers	O
,	O
and	O
our	O
present	O
results	O
suggested	O
that	O
this	O
may	O
be	O
due	O
to	O
the	O
low	O
level	O
of	O
estradiol	B-protein
receptors	I-protein
in	O
the	O
cytosol	O
of	O
mononuclear	B-cell_type
cells	I-cell_type
.	O

Association	O
of	O
increased	O
lytic	O
effector	O
cell	O
function	O
with	O
high	O
estrogen	B-protein
receptor	I-protein
levels	O
in	O
tumor-bearing	O
patients	O
with	O
breast	O
cancer	O
.	O

Tumor-bearing	O
patients	O
with	O
breast	O
cancer	O
were	O
assayed	O
for	O
their	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
activity	O
and	O
for	O
the	O
function	O
of	O
activated	O
cytotoxic	B-cell_type
T-cells	I-cell_type
,	O
as	O
assessed	O
by	O
lectin-dependent	O
cellular	O
cytotoxicity	O
(	O
LDCC	O
)	O
.	O

Tumor-bearing	O
patients	O
with	O
breast	O
cancer	O
had	O
a	O
significant	O
increase	O
in	O
NK	B-cell_type
activity	O
and	O
in	O
LDCC	O
,	O
as	O
compared	O
with	O
healthy	O
control	O
individuals	O
.	O

Although	O
the	O
enhanced	O
NK	B-cell_type
cell	I-cell_type
activity	O
and	O
LDCC	O
were	O
closely	O
associated	O
with	O
high	O
levels	O
(	O
greater	O
than	O
31	O
fmol/mg	O
)	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
content	O
in	O
the	O
primary	O
tumor	O
,	O
no	O
other	O
clinical	O
or	O
histologic	O
correlation	O
between	O
the	O
increase	O
in	O
either	O
parameter	O
of	O
cytotoxic	B-cell_type
effector	I-cell_type
cell	I-cell_type
function	O
could	O
be	O
found	O
.	O

Thus	O
,	O
ER	B-protein
levels	O
greater	O
than	O
31	O
fmol/mg	O
might	O
be	O
associated	O
with	O
increased	O
cytotoxic	B-cell_type
effector	I-cell_type
cell	I-cell_type
function	O
in	O
tumor-bearing	O
patients	O
with	O
breast	O
cancer	O
.	O

Properties	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
Epstein-Barr	B-cell_line
virus-transformed	I-cell_line
lymphocytes	I-cell_line
from	O
patients	O
with	O
familial	O
cortisol	O
resistance	O
.	O

In	O
a	O
previous	O
report	O
of	O
two	O
patients	O
with	O
familial	O
glucocorticoid	O
resistance	O
due	O
to	O
reduced	O
numbers	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
,	O
we	O
have	O
shown	O
decreased	O
numbers	O
of	O
GR	B-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
cultured	B-cell_line
fibroblasts	I-cell_line
but	O
normal	O
affinity	O
of	O
GR	B-protein
in	O
both	O
patients	O
.	O

In	O
this	O
study	O
,	O
peripheral	B-cell_type
lymphocytes	I-cell_type
from	O
these	O
patients	O
,	O
one	O
patient	O
's	O
son	O
and	O
daughter	O
,	O
and	O
normal	O
subjects	O
were	O
transformed	O
with	O
Epstein-Barr	O
virus	O
.	O

Reduced	O
numbers	O
and	O
normal	O
affinity	O
of	O
GR	B-protein
were	O
found	O
in	O
the	O
Epstein-Barr	B-cell_line
virus-transformed	I-cell_line
lymphocytes	I-cell_line
from	O
both	O
patients	O
while	O
the	O
son	O
and	O
daughter	O
had	O
normal	O
numbers	O
and	O
affinity	O
of	O
GR	B-protein
.	O

The	O
thermal	O
stability	O
of	O
GR	B-protein
and	O
thermal	O
activation	O
of	O
cytosolic	B-protein
receptors	I-protein
in	O
both	O
patients	O
were	O
found	O
to	O
be	O
normal	O
.	O

Although	O
the	O
percentages	O
of	O
nuclear	O
bound	O
GR	B-protein
were	O
similar	O
in	O
both	O
patients	O
and	O
normal	O
controls	O
,	O
the	O
absolute	O
amounts	O
of	O
nuclear	O
bound	O
GR	B-protein
of	O
the	O
patients	O
were	O
about	O
one-half	O
that	O
of	O
normal	O
controls	O
.	O

These	O
abnormal	O
properties	O
of	O
GR	B-protein
(	O
reduced	O
numbers	O
of	O
GR	B-protein
)	O
were	O
preserved	O
in	O
the	O
transformed	B-cell_line
cells	I-cell_line
from	O
the	O
patients	O
.	O

Octamer	O
transcription	O
factors	O
1	O
and	O
2	O
each	O
bind	O
to	O
two	O
different	O
functional	B-DNA
elements	I-DNA
in	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
promoter	I-DNA
.	O

Immunoglobulin	B-DNA
heavy-chain	I-DNA
genes	I-DNA
contain	O
two	O
conserved	B-DNA
sequence	I-DNA
elements	I-DNA
5	O
'	O
to	O
the	O
site	O
of	O
transcription	O
initiation	O
:	O
the	O
octamer	O
ATGCAAAT	O
and	O
the	O
heptamer	O
CTCATGA	O
.	O

Both	O
of	O
these	O
elements	O
are	O
required	O
for	O
normal	B-DNA
cell-specific	I-DNA
promoter	I-DNA
function	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
both	O
the	O
ubiquitous	B-protein
and	I-protein
lymphoid-cell-specific	I-protein
octamer	I-protein
transcription	I-protein
factors	I-protein
(	O
OTF-1	B-protein
and	O
OTF-2	B-protein
,	O
respectively	O
)	O
interact	O
specifically	O
with	O
each	O
of	O
the	O
two	O
conserved	B-DNA
sequence	I-DNA
elements	I-DNA
,	O
forming	O
either	O
homo-	B-protein
or	I-protein
heterodimeric	I-protein
complexes	I-protein
.	O

This	O
was	O
surprising	O
,	O
since	O
the	O
heptamer	O
and	O
octamer	O
sequence	O
motifs	O
bear	O
no	O
obvious	O
similarity	O
to	O
each	O
other	O
.	O

Binding	O
of	O
either	O
factor	O
to	O
the	O
octamer	B-DNA
element	I-DNA
occurred	O
independently	O
.	O

However	O
,	O
OTF	B-protein
interaction	O
with	O
the	O
heptamer	B-DNA
sequence	I-DNA
appeared	O
to	O
require	O
the	O
presence	O
of	O
an	O
intact	O
octamer	O
motif	O
and	O
occurred	O
with	O
a	O
spacing	O
of	O
either	O
2	B-DNA
or	I-DNA
14	I-DNA
base	I-DNA
pairs	I-DNA
between	O
the	O
two	O
elements	O
,	O
suggesting	O
coordinate	O
binding	O
resulting	O
from	O
protein-protein	O
interactions	O
.	O

The	O
degeneracy	O
in	O
sequences	O
recognized	O
by	O
the	O
OTFs	B-protein
may	O
be	O
important	O
in	O
widening	O
the	O
range	O
over	O
which	O
gene	O
expression	O
can	O
be	O
modulated	O
and	O
in	O
establishing	O
cell	O
type	O
specificity	O
.	O

Identification	O
of	O
a	O
novel	O
lymphoid	B-protein
specific	I-protein
octamer	I-protein
binding	I-protein
protein	I-protein
(	O
OTF-2B	B-protein
)	O
by	O
proteolytic	O
clipping	O
bandshift	O
assay	O
(	O
PCBA	O
)	O
.	O

The	O
octamer	O
sequence	O
ATGCAAAT	O
is	O
found	O
in	O
the	O
promoters	O
of	O
immunoglobulin	B-DNA
(	I-DNA
Ig	I-DNA
)	I-DNA
heavy	I-DNA
and	I-DNA
light	I-DNA
chain	I-DNA
genes	I-DNA
and	O
in	O
the	O
heavy	B-DNA
chain	I-DNA
enhancer	I-DNA
and	O
is	O
a	O
major	O
determinant	O
of	O
the	O
cell	O
type	O
specific	O
expression	O
of	O
Ig	B-DNA
genes	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
.	O

An	O
apparent	O
paradox	O
is	O
that	O
the	O
same	O
sequence	O
serves	O
as	O
an	O
upstream	B-DNA
promoter	I-DNA
or	I-DNA
enhancer	I-DNA
element	I-DNA
in	O
a	O
variety	O
of	O
housekeeping	B-DNA
genes	I-DNA
such	O
as	O
the	O
histone	B-DNA
H2B	I-DNA
and	I-DNA
U	I-DNA
snRNA	I-DNA
genes	I-DNA
.	O

The	O
differential	O
usage	O
of	O
this	O
regulatory	O
sequence	O
motif	O
is	O
thought	O
to	O
be	O
mediated	O
by	O
different	O
species	O
of	O
octamer	B-protein
binding	I-protein
proteins	I-protein
.	O

One	O
species	O
of	O
100	O
kd	O
,	O
designated	O
OTF-1	B-protein
,	O
is	O
present	O
in	O
all	O
cell	O
types	O
and	O
may	O
exert	O
its	O
activating	O
function	O
only	O
when	O
it	O
can	O
interact	O
with	O
additional	O
adjacent	O
transcription	B-protein
factors	I-protein
.	O

The	O
lymphoid	B-protein
cell	I-protein
specific	I-protein
octamer	I-protein
binding	I-protein
protein	I-protein
of	O
60	O
kd	O
(	O
OTF-2A	B-protein
)	O
specifically	O
stimulates	O
Ig	B-DNA
promoters	I-DNA
which	O
consist	O
essentially	O
of	O
a	O
TATA-box	B-DNA
and	O
an	O
octamer	B-DNA
sequence	I-DNA
upstream	O
of	O
it	O
.	O

Here	O
we	O
present	O
evidence	O
for	O
yet	O
another	O
B	B-protein
cell	I-protein
specific	I-protein
octamer	I-protein
binding	I-protein
protein	I-protein
of	O
75	O
kd	O
(	O
OTF-2B	B-protein
)	O
.	O

From	O
several	O
findings	O
,	O
including	O
the	O
absence	O
of	O
OTF-2B	B-protein
(	O
but	O
not	O
OTF-2A	B-protein
)	O
from	O
a	O
lymphocyte	B-cell_line
line	I-cell_line
that	O
can	O
not	O
respond	O
to	O
the	O
IgH	B-DNA
enhancer	I-DNA
,	O
we	O
propose	O
a	O
role	O
of	O
the	O
novel	B-protein
octamer	I-protein
factor	I-protein
in	O
the	O
long	O
range	O
activation	O
by	O
the	O
IgH	B-DNA
enhancer	I-DNA
.	O

We	O
have	O
used	O
the	O
proteolytic	O
clipping	O
bandshift	O
assay	O
(	O
PCBA	O
)	O
technique	O
to	O
distinguish	O
the	O
three	O
different	O
forms	O
found	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

This	O
analysis	O
indicates	O
that	O
the	O
75	O
kd-species	O
OTF-2B	B-protein
is	O
closely	O
related	O
to	O
the	O
60	B-protein
kd	I-protein
species	I-protein
OTF-2A	I-protein
.	O

Inhibition	O
of	O
interleukin	B-protein
2	I-protein
-induced	O
proliferation	O
of	O
cloned	B-cell_line
murine	I-cell_line
T	I-cell_line
cells	I-cell_line
by	O
glucocorticoids	O
.	O

Possible	O
involvement	O
of	O
an	O
inhibitory	B-protein
protein	I-protein
.	O

The	O
ability	O
of	O
glucocorticoids	O
to	O
inhibit	O
interleukin	B-protein
2	I-protein
(	O
IL	B-protein
2	I-protein
)	O
-induced	O
T	B-cell_type
cell	I-cell_type
proliferation	O
in	O
two	O
cytotoxic	B-cell_line
T	I-cell_line
cell	I-cell_line
(	I-cell_line
CTL	I-cell_line
)	I-cell_line
clones	I-cell_line
has	O
been	O
studied	O
.	O

A	O
complete	O
inhibition	O
of	O
DNA	O
synthesis	O
by	O
dexamethasone	O
(	O
Dx	O
)	O
could	O
be	O
observed	O
when	O
IL	B-cell_line
2-depleted	I-cell_line
cultures	I-cell_line
of	O
CTL	B-cell_line
were	O
either	O
incubated	O
for	O
6	O
h	O
with	O
the	O
hormone	B-protein
prior	O
to	O
the	O
addition	O
of	O
IL	B-protein
2	I-protein
or	O
treated	O
simultaneously	O
with	O
Dx	O
and	O
a	O
low	O
concentration	O
of	O
IL	B-protein
2	I-protein
.	O

No	O
significant	O
reduction	O
in	O
the	O
number	O
and	O
affinity	O
of	O
IL	B-protein
2	I-protein
receptors	I-protein
was	O
seen	O
after	O
6	O
h	O
incubation	O
with	O
Dx	O
.	O

The	O
order	O
of	O
potency	O
observed	O
with	O
the	O
different	O
steroids	O
indicated	O
that	O
this	O
inhibitory	O
effect	O
was	O
mediated	O
through	O
binding	O
to	O
a	O
specific	O
glucocorticoid	B-protein
receptor	I-protein
.	O

The	O
action	O
of	O
these	O
hormones	B-protein
possibly	O
involves	O
the	O
synthesis	O
of	O
an	O
inhibitory	B-protein
protein	I-protein
(	O
s	O
)	O
,	O
since	O
the	O
presence	O
of	O
cycloheximide	O
during	O
the	O
incubation	O
with	O
Dx	O
prevented	O
the	O
inhibition	O
of	O
DNA	O
synthesis	O
.	O

Furthermore	O
,	O
supernatant	O
from	O
Dx-treated	O
CTL	B-cell_line
contained	O
a	O
nondialyzable	O
factor	O
which	O
inhibited	O
DNA	O
synthesis	O
and	O
cell	O
growth	O
of	O
CTL	B-cell_line
clones	I-cell_line
induced	O
by	O
IL	B-protein
2	I-protein
.	O

Blocking	O
of	O
IL	B-protein
2	I-protein
synthesis	O
and	O
IL	B-protein
2	I-protein
receptor	I-protein
formation	O
have	O
been	O
proposed	O
as	O
one	O
of	O
the	O
major	O
mechanisms	O
of	O
glucocorticoid-induced	O
immunosuppression	O
.	O

Our	O
results	O
indicate	O
that	O
these	O
hormones	B-protein
may	O
also	O
affect	O
T	B-cell_type
cell	I-cell_type
proliferation	O
by	O
inhibiting	O
IL	B-protein
2	I-protein
activity	O
.	O

Identification	O
and	O
purification	O
of	O
a	O
human	B-protein
immunoglobulin-enhancer-binding	I-protein
protein	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
that	O
activates	O
transcription	O
from	O
a	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
promoter	I-DNA
in	O
vitro	O
.	O

The	O
enhancer-binding	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
,	O
which	O
is	O
found	O
only	O
in	O
cells	O
that	O
transcribe	O
immunoglobulin	B-DNA
light	I-DNA
chain	I-DNA
genes	I-DNA
,	O
has	O
been	O
purified	O
from	O
nuclear	O
extracts	O
of	O
Namalwa	B-cell_line
cells	I-cell_line
(	O
human	B-cell_line
Burkitt	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
)	O
by	O
sequence-specific	O
DNA	O
affinity	O
chromatography	O
.	O

The	O
purified	O
NF-kappa	B-protein
B	I-protein
has	O
been	O
identified	O
as	O
a	O
51-kDa	B-protein
polypeptide	I-protein
by	O
UV-crosslinking	O
analysis	O
.	O

``	O
Footprint	O
''	O
and	O
methylation-interference	O
analyses	O
have	O
shown	O
that	O
purified	O
NF-kappa	B-protein
B	I-protein
has	O
a	O
binding	O
activity	O
specific	O
for	O
the	O
kappa	B-DNA
light	I-DNA
chain	I-DNA
enhancer	I-DNA
sequence	I-DNA
.	O

The	O
purified	O
factor	O
activated	O
in	O
vitro	O
transcription	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
I	I-DNA
promoter	I-DNA
by	O
binding	O
to	O
an	O
upstream	B-DNA
NF-kappa	I-DNA
B-binding	I-DNA
site	I-DNA

Lymphocyte	B-cell_type
glucocorticoid	B-protein
receptor	I-protein
binding	O
in	O
depression	O
:	O
normal	O
values	O
following	O
recovery	O
.	O

The	O
number	O
of	O
glucocorticoid	B-protein
receptor	I-protein
sites	O
in	O
lymphocytes	B-cell_type
and	O
plasma	O
cortisol	O
concentrations	O
were	O
measured	O
in	O
20	O
patients	O
who	O
had	O
recovered	O
from	O
major	O
depressive	O
disorder	O
and	O
20	O
healthy	O
control	O
subjects	O
.	O

The	O
number	O
of	O
glucocorticoid	B-protein
receptor	I-protein
sites	O
in	O
lymphocytes	B-cell_type
from	O
the	O
recovered	O
depressed	O
group	O
was	O
not	O
significantly	O
different	O
from	O
that	O
of	O
the	O
control	O
group	O
.	O

Although	O
the	O
mean	O
plasma	O
cortisol	O
concentration	O
in	O
recovered	O
depressives	O
was	O
higher	O
than	O
in	O
control	O
subjects	O
,	O
the	O
difference	O
only	O
just	O
reached	O
significance	O
.	O

This	O
study	O
shows	O
that	O
the	O
reduction	O
in	O
glucocorticoid	B-protein
receptor	I-protein
numbers	O
which	O
occurs	O
during	O
acute	O
depressive	O
illness	O
does	O
not	O
persist	O
on	O
recovery	O
and	O
is	O
,	O
therefore	O
,	O
state-dependent	O
.	O

Identification	O
and	O
purification	O
of	O
a	O
human	B-protein
lymphoid-specific	I-protein
octamer-binding	I-protein
protein	I-protein
(	O
OTF-2	B-protein
)	O
that	O
activates	O
transcription	O
of	O
an	O
immunoglobulin	B-DNA
promoter	I-DNA
in	O
vitro	O
.	O

The	O
octamer	O
sequence	O
5'-ATGCAAAT	O
,	O
in	O
either	O
orientation	O
,	O
serves	O
as	O
an	O
upstream	B-DNA
element	I-DNA
in	O
a	O
variety	O
of	O
promoters	B-DNA
and	O
also	O
occurs	O
as	O
a	O
modular	B-DNA
enhancer	I-DNA
element	I-DNA
.	O

It	O
is	O
of	O
particular	O
interest	O
in	O
immunoglobulin	B-DNA
genes	I-DNA
since	O
it	O
is	O
found	O
in	O
the	O
upstream	B-DNA
regions	I-DNA
of	O
all	O
heavy	B-DNA
and	I-DNA
light	I-DNA
chain	I-DNA
promoters	I-DNA
and	O
in	O
the	O
heavy	B-DNA
chain	I-DNA
enhancer	I-DNA
,	O
both	O
of	O
which	O
are	O
known	O
to	O
be	O
necessary	O
for	O
cell-specific	O
expression	O
.	O

We	O
report	O
here	O
the	O
chromatographic	O
separation	O
of	O
ubiquitous	B-protein
and	I-protein
B	I-protein
cell-specific	I-protein
octamer-binding	I-protein
proteins	I-protein
.	O

The	O
B	B-protein
cell	I-protein
factor	I-protein
was	O
purified	O
to	O
homogeneity	O
using	O
affinity	O
chromatography	O
and	O
consists	O
of	O
three	O
peptides	O
of	O
62	O
,	O
61	O
,	O
and	O
58.5	O
+/-	O
1.5	O
kd	O
.	O

Each	O
of	O
the	O
polypeptides	O
was	O
renatured	O
after	O
SDS-PAGE	O
and	O
shown	O
to	O
bind	O
to	O
the	O
octamer	O
sequence	O
.	O

The	O
specific	O
DNA	O
binding	O
activity	O
of	O
the	O
pure	O
B	B-protein
cell-specific	I-protein
factor	I-protein
was	O
indistinguishable	O
from	O
that	O
of	O
the	O
affinity-purified	B-protein
ubiquitous	I-protein
factor	I-protein
.	O

This	O
B	B-protein
cell-specific	I-protein
octamer-binding	I-protein
factor	I-protein
,	O
in	O
pure	O
form	O
,	O
activated	O
transcription	O
from	O
a	O
kappa	B-DNA
light	I-DNA
chain	I-DNA
promoter	I-DNA
in	O
vitro	O
,	O
thus	O
demonstrating	O
that	O
it	O
is	O
indeed	O
a	O
B	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
for	O
this	O
gene	O
.	O

In	O
addition	O
to	O
the	O
ubiquitous	B-protein
and	I-protein
B	I-protein
cell-specific	I-protein
octamer-binding	I-protein
factors	I-protein
,	O
we	O
identified	O
several	O
additional	O
proteins	O
,	O
one	O
of	O
which	O
is	O
B	B-cell_type
cell	I-cell_type
-specific	O
,	O
that	O
interact	O
with	O
the	O
kappa	B-DNA
promoter	I-DNA
.	O

Decreased	O
deoxyribonucleic	O
acid	O
binding	O
of	O
glucocorticoid-receptor	B-protein
complex	I-protein
in	O
cultured	O
skin	B-cell_line
fibroblasts	I-cell_line
from	O
a	O
patient	O
with	O
the	O
glucocorticoid	O
resistance	O
syndrome	O
.	O

A	O
patient	O
with	O
the	O
syndrome	O
of	O
glucocorticoid	O
resistance	O
was	O
studied	O
.	O

A	O
27-yr-old	O
woman	O
initially	O
was	O
diagnosed	O
as	O
having	O
Cushing	O
's	O
disease	O
,	O
based	O
on	O
the	O
findings	O
of	O
high	O
plasma	O
ACTH	O
and	O
serum	O
cortisol	O
levels	O
,	O
increased	O
urinary	O
cortisol	O
secretion	O
,	O
resistance	O
to	O
adrenal	O
suppression	O
with	O
dexamethasone	O
,	O
and	O
bilateral	O
adrenal	O
hyperplasia	O
by	O
computed	O
tomography	O
and	O
scintigraphy	O
of	O
the	O
adrenal	O
glands	O
.	O

However	O
,	O
she	O
had	O
no	O
signs	O
or	O
symptoms	O
of	O
Cushing	O
's	O
syndrome	O
.	O

During	O
a	O
5-yr	O
follow-up	O
,	O
no	O
clinical	O
abnormalities	O
developed	O
,	O
although	O
hypercortisolism	O
persisted	O
.	O

End-organ	O
resistance	O
to	O
cortisol	O
was	O
suspected	O
.	O

To	O
explain	O
the	O
end-organ	O
resistance	O
to	O
cortisol	O
,	O
the	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
and	O
cultured	B-cell_line
skin	I-cell_line
fibroblasts	I-cell_line
from	O
a	O
forearm	O
skin	O
biopsy	O
were	O
characterized	O
and	O
compared	O
with	O
the	O
results	O
of	O
similar	O
studies	O
in	O
normal	O
subjects	O
.	O

The	O
patient	O
's	O
GR	B-protein
in	O
whole	O
cell	O
assays	O
had	O
an	O
increased	O
dissociation	O
constant	O
(	O
Kd	O
)	O
.	O

In	O
the	O
cytosol	O
of	O
cultured	B-cell_line
skin	I-cell_line
fibroblasts	I-cell_line
from	O
the	O
patient	O
,	O
there	O
was	O
also	O
decreased	O
binding	O
capacity	O
.	O

The	O
thermal	O
stability	O
and	O
the	O
sedimentation	O
coefficient	O
in	O
a	O
sucrose	O
density	O
gradient	O
of	O
the	O
receptors	O
in	O
the	O
cytosol	O
of	O
cultured	B-cell_line
skin	I-cell_line
fibroblasts	I-cell_line
from	O
the	O
patient	O
and	O
normal	O
subjects	O
were	O
similar	O
.	O

GR	B-cell_line
complex	I-cell_line
activation	I-cell_line
,	O
analyzed	O
by	O
DEAE-cellulose	B-cell_line
chromatography	I-cell_line
,	O
was	O
decreased	O
in	O
the	O
patient	O
.	O

DNA	B-DNA
binding	O
of	O
the	O
GR	B-protein
complex	I-protein
after	O
temperature-induced	O
activation	O
was	O
lower	O
in	O
the	O
patient	O
than	O
in	O
normal	O
subjects	O
.	O

Nuclear	O
translocation	O
of	O
GR	B-protein
complexes	I-protein
from	O
the	O
patient	O
was	O
also	O
slightly	O
decreased	O
.	O

These	O
results	O
suggest	O
that	O
the	O
patient	O
's	O
glucocorticoid	O
resistance	O
was	O
due	O
to	O
a	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
receptor	O
for	O
glucocorticoids	O
and	O
a	O
decrease	O
in	O
the	O
binding	O
of	O
the	O
GR	B-protein
complex	I-protein
to	O
DNA	B-DNA
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
.	O

Sensitive	O
and	O
receptor-mediated	O
regulation	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
in	O
normal	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
.	O

We	O
show	O
that	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
[	O
OH	O
]	O
2D3	O
)	O
,	O
the	O
most	O
hormonally	O
active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
modulates	O
sensitively	O
and	O
specifically	O
both	O
the	O
protein	O
and	O
messenger	B-RNA
RNA	I-RNA
accumulation	O
of	O
the	O
multilineage	B-protein
growth	I-protein
factor	I-protein
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
.	O

The	O
regulation	O
of	O
GM-CSF	B-protein
expression	O
is	O
seen	O
in	O
both	O
normal	B-cell_type
human	I-cell_type
mitogen-activated	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
T	B-cell_line
lymphocytes	I-cell_line
from	I-cell_line
a	I-cell_line
line	I-cell_line
(	I-cell_line
S-LB1	I-cell_line
)	I-cell_line
transformed	I-cell_line
with	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lymphotropic	I-cell_line
virus	I-cell_line
1	I-cell_line
(	O
HTLV-1	O
)	O
.	O

In	O
contrast	O
,	O
cells	O
from	O
a	O
HTLV-1	B-cell_line
transformed	I-cell_line
T	I-cell_line
lymphocyte	I-cell_line
line	I-cell_line
(	O
Ab-VDR	B-cell_line
)	O
established	O
from	O
a	O
patient	O
with	O
vitamin	O
